Cargando…

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

BACKGROUND: Impairment of cognitive functioning has been reported in several studies in patients treated with chemotherapy. So far, no studies have been published on the effects of the vascular endothelial growth factor receptor (VEGFR) inhibitors on cognitive functioning. We investigated the object...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulder, Sasja F, Bertens, Dirk, Desar, Ingrid ME, Vissers, Kris CP, Mulders, Peter FA, Punt, Cornelis JA, van Spronsen, Dick-Johan, Langenhuijsen, Johan F, Kessels, Roy PC, van Herpen, Carla ML
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987809/ https://www.ncbi.nlm.nih.gov/pubmed/24661373 http://dx.doi.org/10.1186/1471-2407-14-219

Ejemplares similares

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)

Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study
por: Desar, I.M.E., et al.
Publicado: (2011)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer
por: Krens, Stefanie D., et al.
Publicado: (2021)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
por: Desar, I M E, et al.
Publicado: (2010)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist
por: Gole, Prachi, et al.
Publicado: (2014)

Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib
por: Fiorio Pla, Alessandra, et al.
Publicado: (2014)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses
por: Shu, Mao, et al.
Publicado: (2016)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib
por: Di Fiore, F, et al.
Publicado: (2011)

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study
por: Ambring, Anneli, et al.
Publicado: (2012)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
por: Randrup Hansen, Caroline, et al.
Publicado: (2017)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

A short add-on sleep intervention in the rehabilitation of individuals with acquired brain injury: A randomized controlled trial
por: Pilon, Louise, et al.
Publicado: (2023)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Coppin, Chris
Publicado: (2010)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

A randomized controlled trial on errorless learning in goal management training: study rationale and protocol
por: Bertens, Dirk, et al.
Publicado: (2013)

Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3)
por: Yamamoto, Kazuhiro, et al.
Publicado: (2014)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

Organ Atrophy Induced by Sorafenib and Sunitinib – Quantitative Computed Tomography (CT) Evaluation of the Pancreas, Thyroid Gland and Spleen
por: Takahashi, Hiroaki, et al.
Publicado: (2016)

Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis
por: Liu, Xiu-Lan, et al.
Publicado: (2020)

Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2019)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019)

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue
por: Prinsen, Hetty, et al.
Publicado: (2015)

Can we predict prostate size by scoring baldness? The relationship of androgenic alopecia and lower urinary tract symptoms
por: Aourag, Nassim, et al.
Publicado: (2019)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
por: Que, Yi, et al.
Publicado: (2018)

Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study
por: Gu, Liangyou, et al.
Publicado: (2017)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tais6nasib0f86cvechl2alp2m